Products containing naphthalen-1-yl-(1-pentylindol-3-yl) methanone (JWH-018) and naphthalen-1-yl-(1-butylindol-3-yl) methanone (JWH-073) are emerging drugs of abuse. Here, the behavioral effects of JWH-018 and JWH-073 were examined in one behavioral assay selective for cannabinoid agonism, rhesus monkeys (n = 4) discriminating Δ 9-tetrahydrocannabinol (Δ 9-THC; 0.1 mg/kg i.v.), and another assay sensitive to cannabinoid withdrawal, i.e., monkeys (n = 3) discriminating the cannabinoid antagonist rimonabant (1 mg/kg i.v.) during chronic Δ 9-THC (1 mg/kg s.c. 12 h) treatment. Δ 9-THC, JWH-018, and JWH-073 increased drug-lever responding in monkeys discriminating Δ 9- THC; the ED 50 values were 0.044, 0.013, and 0.058 mg/kg, respectively and the duration of action was 4, 2, and 1 h, respectively. Rimonabant (0.32-3.2 mg/kg) produced surmountable antagonism of Δ 9-THC, JWH-018, and JWH-073. Schild analyses and single-dose apparent affinity estimates yielded apparent pA 2/pK B values of 6.65, 6.68, and 6.79 in the presence of Δ 9-THC, JWH-018, and JWH- 073, respectively. In Δ 9-THC-treated monkeys discriminating rimonabant, the training drug increased responding on the rimonabant lever; the ED 50 value of rimonabant was 0.20 mg/kg. Δ 9- THC (1-10 mg/kg), JWH-018 (0.32-3.2 mg/kg), and JWH-073 (3.2-32 mg/kg) dose-dependently attenuated the rimonabantdiscriminative stimulus (i.e., withdrawal). These results suggest that Δ 9-THC, JWH-018, and JWH-073 act through the same receptors to produce Δ 9-THC-like subjective effects and attenuate Δ 9-THC withdrawal. The relatively short duration of action of JWH- 018 and JWH-073 might lead to more frequent use, which could strengthen habitual use by increasing the frequency of stimulusoutcome pairings. This coupled with the possible greater efficacy of JWH-018 at cannabinoid 1 receptors could be associated with greater dependence liability than Δ 9-THC.
|Original language||English (US)|
|Number of pages||9|
|Journal||Journal of Pharmacology and Experimental Therapeutics|
|State||Published - Jan 2012|
ASJC Scopus subject areas
- Molecular Medicine